Intrinsiqq

BioStem Technologies Inc. (BSEM) Quality Score

BSEM
Quality84

Growth remains strong (avg 100/100), but business quality is pulling the composite down (avg 75/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
100/100
1.4x

Under 20x, reasonable relative to earnings

Cash Flow Multiple
100/100
1.5x

Under 20x cash flow, well covered

Not enough quarterly data
for a 1-year trend

Revenue Growth
100/100
311.2%

Above 10% CAGR, strong compounder

Cash Flow Growth
60/100
Just turned +

Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful

Business Quality & Capital Allocation

Share Dilution
0/100
48.3%

Heavy dilution above 5%

Margin Trend
100/100
+47.3pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$18M

Net cash position, no leverage concern

2021
$340333
$5M
2022
$772136
$5M
2023
$239406
$5M
2024
$23M
$4M
Return on Capital
100/100
124.8%

Above 20%, exceptional capital efficiency

Customize WeightsPremiumUpgrade

BioStem Technologies (BSEM) quality: score, margins and returns

BioStem Technologies (BSEM) scores 84/100 on Intrinsiqq's quality score (a high-quality business), a weighted blend of 7 metrics each scored 0 to 100, on 10.3% operating margins and 124.8% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is BioStem Technologies (BSEM) a high-quality business?+

BioStem Technologies scores 84 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a high-quality business on these measures. Recent figures include a 10.3% operating margin and a 124.8% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does BioStem Technologies's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BSEM's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where BioStem Technologies scores well and where it falls behind.

What is BioStem Technologies's return on invested capital (ROIC)?+

BioStem Technologies earns about 124.8% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to BSEM's margins and growth on this scorecard to judge durability.

How profitable is BioStem Technologies?+

BioStem Technologies runs an operating margin of about 10.3% and a net margin of about 10.6%. Revenue has grown at roughly 230.8% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

How the market compares: US profitability statistics

Related stocks: Biotechnology

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.